Core Insights - Cardiff Oncology is focusing on the treatment landscape for first-line RAS-mutated metastatic colorectal cancer (mCRC) and the potential of its PLK1 inhibitor, onvansertib, to enhance patient outcomes when combined with standard therapies [2][3] Industry Context - March is recognized as national colorectal cancer awareness month, highlighting the importance of understanding prevention, detection, and treatment of colorectal cancers [3] - In 2025, over 154,000 patients in the U.S. were diagnosed with colorectal cancer, with nearly 53,000 fatalities, indicating a significant public health issue [3] - There has been limited progress in treating first-line RAS-mutated mCRC, revealing a substantial unmet medical need in this area [3]

Summary of Cardiff Oncology Conference Call Company and Industry Overview - **Company**: Cardiff Oncology (NasdaqCM:CRDF) - **Industry**: Oncology, specifically focusing on colorectal cancer treatment Core Points and Arguments 1. **Treatment Landscape**: Discussion centered on the treatment of first-line RAS mutated metastatic colorectal cancer (mCRC) and the potential of Cardiff's PLK1 inhibitor, onvansertib, to improve patient outcomes when combined with standard therapies [2][3][19] 2. **Colorectal Cancer Statistics**: In 2025, over 154,000 patients in the U.S. were diagnosed with colorectal cancer, with nearly 53,000 deaths attributed to the disease [2] 3. **Unmet Need**: Despite extensive research, there has been limited progress in treating first-line RAS mutated mCRC, highlighting a significant unmet medical need [3] 4. **Clinical Data**: The ongoing Phase II study involves 110 patients with RAS mutations, focusing on dose-finding for onvansertib in combination with standard chemotherapy regimens [7][8] 5. **Objective Response Rates**: The study reported an overall objective response rate of 72.2% for the 30 mg onvansertib arm combined with FOLFIRI-bev, significantly higher than the historical response rates of approximately 40-43% for standard therapies [9][10] 6. **Progression-Free Survival (PFS)**: Median PFS for the standard of care was approximately 11 months, while the PFS for the onvansertib arms has not yet been reached, indicating potential for longer-term benefits [11][12] 7. **Tolerability**: The combination of onvansertib with chemotherapy showed no significant increase in toxicity, suggesting a favorable safety profile [13][39] 8. **Regulatory Plans**: Cardiff plans to advance the 30 mg dose of onvansertib in combination with FOLFIRI-bev into a registrational program with the FDA [14] Additional Important Insights 1. **Molecular Characterization**: Emphasis on the importance of molecular profiling (KRAS, NRAS, BRAF, MSI-H) to guide treatment decisions in mCRC [19][25] 2. **First-Line Treatment Importance**: The efficacy of cytotoxic agents tends to decline in later treatment lines, making first-line treatment critical for patient outcomes [25][26] 3. **Potential for Curative Surgery**: High response rates may lead to curative surgeries, which is particularly significant in colorectal cancer where long-term survival can be achieved [72][96] 4. **Future Directions**: Discussion on the potential of antibody-drug conjugates (ADCs) and other novel therapies to enhance treatment efficacy in mCRC [81][84] 5. **Current Treatment Limitations**: Acknowledgment that many patients with RAS mutations still rely on traditional chemotherapy regimens, indicating a need for innovative therapies [62][63] This summary encapsulates the key points discussed during the conference call, focusing on Cardiff Oncology's advancements in treating RAS mutated metastatic colorectal cancer and the broader implications for the oncology field.

Core Insights - Cardiff Oncology, Inc. is hosting a KOL webinar to discuss the treatment landscape for first-line RAS-mutated metastatic colorectal cancer (mCRC) on March 25, 2026 [1] - The webinar will feature key opinion leaders Scott Kopetz, M.D., Ph.D., FACP and Heinz-Josef Lenz, M.D., alongside interim CEO Mani Mohindru, focusing on the clinical data of onvansertib and its potential in mCRC management [2] Company Overview - Cardiff Oncology is a clinical-stage biotechnology company focused on developing innovative cancer treatments through PLK1 inhibition, with its lead asset onvansertib currently in a Phase 2 trial for first-line treatment of RAS-mutated mCRC [6] - Onvansertib targets a significant patient population with high unmet needs and is also being investigated in other PLK1-driven cancers, demonstrating robust clinical activity in challenging tumors [6] Key Opinion Leaders - Scott Kopetz, M.D., Ph.D., FACP, is a recognized leader in colorectal cancer research, focusing on new treatment approaches for molecularly defined colorectal cancers and has led numerous clinical studies [3] - Heinz-Josef Lenz, M.D., is a professor with a focus on molecular mechanisms of cancer and biomarker-driven treatment approaches, holding leadership roles in national oncology research initiatives [4] Webinar Details - Interested parties can register for the live webcast on Cardiff Oncology's website, with a replay available post-discussion [5]

Core Insights - Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing novel cancer therapies through PLK1 inhibition [3] Group 1: Upcoming Conferences - Company management will participate in three investor conferences in March 2026, including the TD Cowen 46th Annual Health Care Conference on March 4, Barclays 28th Annual Global Healthcare Conference on March 10, and Leerink Partners Global Healthcare Conference on March 11 [2] Group 2: Company Overview - Cardiff Oncology's lead asset, onvansertib, is a specific oral PLK1 inhibitor currently in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), targeting a large, underserved patient population [3] - Onvansertib is also being investigated in other PLK1-driven cancers through ongoing investigator-initiated trials and has demonstrated robust clinical activity in difficult-to-treat tumors [3] - The company's goal is to target tumor vulnerabilities to overcome treatment resistance and improve clinical outcomes for patients [3]

Summary of Cardiff Oncology FY Conference Call Company Overview - **Company**: Cardiff Oncology (NasdaqCM:CRDF) - **Lead Program**: Onvansertib, a highly selective PLK1 inhibitor targeting first-line RAS mutated metastatic colorectal cancer (mCRC) [2][3] Core Points and Arguments - **Market Opportunity**: The colorectal cancer market is significant, with approximately 150,000 new cases annually and over 55,000 expected deaths by 2027. The five-year survival rate for metastatic colorectal cancer remains low at 15% [7][8]. - **Unmet Need**: There are currently no approved drugs specifically for RAS mutated mCRC, highlighting a substantial unmet medical need [8][9]. - **Efficacy Data**: - Onvansertib demonstrated a confirmed overall response rate (ORR) of 72% when combined with FOLFIRI and bevacizumab, representing a 30% improvement over the standard of care [4][20]. - The median progression-free survival (PFS) has not yet been reached in the onvansertib arm, while the standard of care arm has a median PFS of approximately 11 months [21][22]. - The study showed favorable dose-dependent trends and PFS hazard ratios, indicating potential for practice-changing outcomes in underserved populations [5][22]. - **Regulatory Path**: The company plans to finalize a path to registration for onvansertib in frontline RAS-mutated mCRC after discussions with the FDA, aiming to provide a full plan within the first half of 2026 [6][27]. Competitive Landscape - **Current Treatments**: The standard of care for first-line mCRC has remained largely unchanged, primarily involving combinations of chemotherapy with bevacizumab [8][9]. - **Unique Positioning**: Onvansertib is positioned as the only program specifically designed for the entire RAS-mutated population, differentiating it from mutation-specific therapies currently in development [9][10]. Additional Insights - **Combination Potential**: Onvansertib shows promise not only in mCRC but also in other RAS-driven cancers, such as chronic myelomonocytic leukemia (CMML) [30][31]. - **Cash Position**: Cardiff Oncology reported $58.3 million in cash equivalents, sufficient to fund operations into the first quarter of 2027, although this does not include significant investments for the phase 3 study [33][34]. - **Clinical Benefit**: The company believes that the totality of data, including ORR, PFS, and hazard ratios, supports the clinical benefit of onvansertib, which is compelling for regulatory discussions [36][39]. Future Outlook - **Upcoming Milestones**: Cardiff Oncology plans to share more detailed data from the ongoing phase 2 study and regulatory feedback in the first half of 2026, with a focus on advancing to phase 3 trials [31][32][27].

Core Insights - Cardiff Oncology reported positive results from the Phase 2 CRDF-004 trial for first-line RAS-mutated metastatic colorectal cancer (mCRC), showing a robust objective response rate (ORR) of 72.2% with the 30 mg onvansertib + FOLFIRI/bev combination, compared to 43.2% with standard of care (SoC) [1][5] - The trial also demonstrated a significant improvement in progression-free survival (PFS) with a hazard ratio (HR) of 0.37, indicating a strong potential for onvansertib to enhance patient outcomes [1][5] - The company plans to advance the 30 mg dose of onvansertib into a registrational program, with detailed data and plans expected in the first half of 2026 [1][2] Clinical Development - The CRDF-004 trial results indicate a consistent, dose-dependent treatment benefit, with nearly a 30% improvement in response rate over the control arm and encouraging durability trends in PFS [2][5] - The company has not observed significant added toxicity with the 30 mg onvansertib dose in combination with FOLFIRI/bev, supporting its advancement into registrational development [5] Financial Performance - For the year ended December 31, 2025, Cardiff Oncology reported total operating expenses of approximately $49.6 million, a slight increase from $49.3 million in 2024, primarily due to higher selling, general, and administrative expenses [8][14] - The company reported a net loss of $45.876 million for 2025, compared to a net loss of $45.455 million in 2024, with a net loss per common share of $0.69 [14] - As of December 31, 2025, Cardiff had approximately $58.3 million in cash and cash equivalents, sufficient to fund operations into the first quarter of 2027 [7] Leadership Changes - In January 2026, Cardiff announced executive leadership changes to support its transition into late-stage clinical development, appointing Mani Mohindru as interim Chief Executive Officer [4] - The company is actively searching for a permanent Chief Executive Officer and Chief Financial Officer to strengthen its leadership team [4]

Core Insights - Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing novel cancer therapies through PLK1 inhibition [3] - The company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026, with a live webcast available for interested parties [1][2] Company Overview - Cardiff Oncology is advancing innovative cancer treatments, particularly targeting PLK1 inhibition, which is recognized as a validated oncology target with significant potential to change clinical practice [3] - The lead asset, onvansertib, is an oral PLK1 inhibitor currently in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large patient population with high unmet needs [3] - Onvansertib is also being investigated in other PLK1-driven cancers through ongoing investigator-initiated trials and has demonstrated robust clinical activity as a single agent in challenging tumors [3]

Core Viewpoint - Cardiff Oncology Inc. experienced a significant decline of approximately 32% in stock price following management and trial updates, indicating investor concern over leadership changes and clinical trial focus [1][9]. Management Changes - Mani Mohindru has been appointed as interim CEO, effective immediately, following the resignation of CEO Mark Erlander and CFO James Levine [1][2]. - Brigitte Lindsay has been promoted to Chief Accounting Officer to ensure financial continuity, having been with the company for over 14 years [2]. Clinical Trial Update - Cardiff Oncology provided an update on the CRDF-004 trial, which is a Phase 2 study evaluating onvansertib in combination with standard care regimens for patients with RAS-mutated metastatic colorectal cancer [3]. - The trial showed a 72.2% confirmed objective response rate in the 30 mg dose group of onvansertib with FOLFIRI/bevacizumab, compared to 43.2% in the standard care group, approaching statistical significance (p-value = 0.051) [4]. - Progression-free survival was statistically significant for the 30 mg onvansertib plus FOLFIRI/bevacizumab group (p-value = 0.048), with median progression-free survival not yet reached in the treatment groups [5]. Future Plans - Based on the trial results, the company plans to advance the 30 mg dose of onvansertib with FOLFIRI/bevacizumab into a registrational trial for first-line patients with RAS-mutated metastatic colorectal cancer, pending FDA consultation [6]. - The focus will be narrowed to onvansertib in combination with FOLFIRI, which may reduce the total addressable market in the frontline setting to 12%-20% from a previous estimate of 40%-50% [8]. Analyst Commentary - Analysts from William Blair expressed concerns regarding the abrupt management changes and the narrowed focus on onvansertib with FOLFIRI, leading to a reduction in the probability of success from 50% to 45% [8]. - Despite the concerns, William Blair maintains an Outperform rating for the stock [9].

Summary of Cardiff Oncology Update Call Company Overview - **Company**: Cardiff Oncology (NasdaqCM:CRDF) - **Focus**: Development of onvansertib, a highly specific oral PLK1 inhibitor, primarily for RAS-mutated metastatic colorectal cancer (mCRC) patients Key Points Management Transition - Cardiff Oncology announced a management transition to better position the company for late-stage development of onvansertib [5][6] - Mani Mohindru appointed as Interim CEO, emphasizing the need for leadership aligned with the company's evolving operational and financial needs [4][5] Clinical Trial Updates - Promising phase 2 data from the CRDF-004 trial for onvansertib in first-line RAS-mutated mCRC patients was discussed [5][7] - The trial evaluated onvansertib in combination with standard care regimens (FOLFIRI plus bevacizumab or FOLFOX plus bevacizumab) [8] - Dose-dependent benefits observed, particularly with the 30 mg dose of onvansertib combined with FOLFIRI plus bevacizumab, showing an overall objective response rate of 72.2% compared to 43.2% with FOLFOX and 42.1% with FOLFIRI alone [10][11] Efficacy and Safety Data - Median progression-free survival (PFS) has not yet been reached in the onvansertib arms, indicating extended benefit compared to a median PFS of about 11 months for standard care [10] - The PFS hazard ratio was reported at 0.37 for the 30 mg onvansertib plus FOLFIRI bev arm, indicating a significant reduction in disease progression risk [11] - Safety profile remains favorable, with no unexpected toxicities reported; grade 3 or higher adverse events were infrequent [12] Future Plans - Cardiff plans to initiate a registrational study later in 2026, comparing onvansertib plus FOLFIRI to standard care regimens [12][14] - The study protocol will likely include both FOLFIRI and FOLFOX in the control arm to provide comprehensive data for regulatory review [13] - Anticipation of more mature clinical data from the CRDF-004 study by mid-2026 [14] Strategic Considerations - Discussions regarding potential partnerships to support the phase 3 trial and broaden development beyond initial indications are ongoing [33] - The company is focused on building a leadership team with experience in late-stage development and commercialization [76] Additional Insights - The transition in leadership is not due to issues with onvansertib but rather a strategic move to capitalize on promising data [6] - The focus on durability of response is emphasized, with stable disease being a significant factor in treatment efficacy [24][25] - The company is committed to maintaining operational continuity during the management transition [7] Conclusion Cardiff Oncology is positioned for significant growth with onvansertib, supported by promising clinical data and a strategic management transition aimed at enhancing its late-stage development efforts. The upcoming registrational study and potential partnerships are critical steps in advancing the drug's market potential.

Core Insights - Cardiff Oncology, Inc. announced positive results from the CRDF-004 Phase 2 clinical trial, demonstrating that onvansertib combined with FOLFIRI/bevacizumab (bev) shows dose-dependent improvements in overall response rates and progression-free survival (PFS) in patients with RAS-mutated metastatic colorectal cancer (mCRC) [1][3][4] Group 1: Clinical Trial Results - The trial showed that the 30 mg dose of onvansertib with FOLFIRI/bev is selected for further registrational trials based on its efficacy [2][3] - In the intent-to-treat analysis, onvansertib with FOLFIRI/bev outperformed both standard of care (SoC) regimens, with a confirmed objective response rate (ORR) of 44.4% for the 30 mg dose [1][3] - Median PFS for the 30 mg onvansertib group was not reached, indicating a potential benefit over SoC [3][4] Group 2: Safety and Tolerability - Onvansertib was reported to be safe and well-tolerated, with no significant additive toxicity observed in the trial [1][3] - Grade 3 or higher adverse events were infrequent, with neutropenia being the most common treatment-emergent adverse event [5] Group 3: Future Plans - Cardiff Oncology plans to initiate a registrational program later this year, pending finalization of trial design in consultation with the FDA [2][3] - The company expects to provide final data and registrational plans in the first half of 2026 [1][3] Group 4: Industry Context - There is a significant unmet need for improved first-line treatment options for patients with RAS-mutated mCRC, as current treatments have not significantly advanced in over two decades [5] - Onvansertib's novel mechanism of action and promising preliminary results support the need for further investigation in a large Phase 3 trial [5]